A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Bactroban Pharmacology, Pharmacokinetics, Studies, Metabolism - Mupirocin
Bactroban Pharmacology, Pharmacokinetics, Studies, Metabolism - Mupirocin
CLINICAL PHARMACOLOGY
Mupirocin is produced by fermentation
of the organism Pseudomonas
fluorescens. Mupirocin inhibits bacterial protein
synthesis by reversibly
and specifically binding to bacterial isoleucyl transfer-RNA synthetase.
Due to this mode of action, mupirocin
shows no cross resistance
with chloramphenicol, erythromycin, fusidic acid, gentamicin, lincomycin,
methicillin, neomycin, novobiocin, penicillin, streptomycin, and
tetracycline.
Application of 14C-labeled mupirocin
ointment to the lower
arm of normal male
subjects followed by occlusion
for 24 hours showed no measurable systemic
absorption (<1.1
nanogram mupirocin
per milliliter of whole
blood). Measurable radioactivity was present
in the stratum corneum
of these subjects 72 hours after application.
Microbiology: The following bacteria
are susceptible
to the action of mupirocin
in vitro: the aerobic
isolates of Staphylococcus aureus (including methicillin-resistant
and b-lactamase producing strains), Staphylococcus
epidermidis, Staphylococcus
saprophyticus, and Streptococcus
pyogenes.
Only the organisms listed in INDICATIONS
AND USAGE have been shown to be clinically susceptible
to mupirocin.
top
